Literature DB >> 24887457

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma.

Michael R Green1, Carolina Vicente-Dueñas2, Isabel Romero-Camarero3, Chih Long Liu4, Bo Dai4, Inés González-Herrero3, Idoia García-Ramírez3, Esther Alonso-Escudero3, Javeed Iqbal5, Wing C Chan5, Elena Campos-Sanchez6, Alberto Orfao7, Belén Pintado8, Teresa Flores9, Oscar Blanco10, Rafael Jiménez11, Jose Angel Martínez-Climent12, Francisco Javier García Criado13, María Begoña García Cenador13, Shuchun Zhao14, Yasodha Natkunam14, Izidore S Lossos15, Ravindra Majeti4, Ari Melnick16, César Cobaleda6, Ash A Alizadeh1, Isidro Sánchez-García2.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma and can be separated into two subtypes based upon molecular features with similarities to germinal centre B-cells (GCB-like) or activated B-cells (ABC-like). Here we identify gain of 3q27.2 as being significantly associated with adverse outcome in DLBCL and linked with the ABC-like subtype. This lesion includes the BCL6 oncogene, but does not alter BCL6 transcript levels or target-gene repression. Separately, we identify expression of BCL6 in a subset of human haematopoietic stem/progenitor cells (HSPCs). We therefore hypothesize that BCL6 may act by 'hit-and-run' oncogenesis. We model this hit-and-run mechanism by transiently expressing Bcl6 within murine HSPCs, and find that it causes mature B-cell lymphomas that lack Bcl6 expression and target-gene repression, are transcriptionally similar to post-GCB cells, and show epigenetic changes that are conserved from HSPCs to mature B-cells. Together, these results suggest that BCL6 may function in a 'hit-and-run' role in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24887457      PMCID: PMC4321731          DOI: 10.1038/ncomms4904

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  70 in total

1.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

Review 2.  Leukaemia stem cells and the evolution of cancer-stem-cell research.

Authors:  Brian J P Huntly; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

3.  Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development.

Authors:  Kyongrim Kwon; Caroline Hutter; Qiong Sun; Ivan Bilic; César Cobaleda; Stephen Malin; Meinrad Busslinger
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

4.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

5.  Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas.

Authors:  I S Lossos; A A Alizadeh; M B Eisen; W C Chan; P O Brown; D Botstein; L M Staudt; R Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

Review 6.  Pathogenesis of human B cell lymphomas.

Authors:  Arthur L Shaffer; Ryan M Young; Louis M Staudt
Journal:  Annu Rev Immunol       Date:  2012-01-06       Impact factor: 28.527

7.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

Review 8.  The evolving contribution of hematopoietic progenitor cells to lymphomagenesis.

Authors:  Oliver Weigert; David M Weinstock
Journal:  Blood       Date:  2012-08-06       Impact factor: 22.113

9.  GSEA-P: a desktop application for Gene Set Enrichment Analysis.

Authors:  Aravind Subramanian; Heidi Kuehn; Joshua Gould; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2007-07-20       Impact factor: 6.937

10.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

View more
  43 in total

Review 1.  Clonal hematopoiesis.

Authors:  Max Jan; Benjamin L Ebert; Siddhartha Jaiswal
Journal:  Semin Hematol       Date:  2016-10-20       Impact factor: 3.851

Review 2.  Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2015-02-03       Impact factor: 2.490

3.  Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.

Authors:  Rohit Mathur; Lalit Sehgal; Ondrej Havranek; Stefan Köhrer; Tamer Khashab; Neeraj Jain; Jan A Burger; Sattva S Neelapu; R Eric Davis; Felipe Samaniego
Journal:  Haematologica       Date:  2016-10-14       Impact factor: 9.941

4.  BCL6 locus is hypermethylated in angioimmunoblastic T-cell lymphoma.

Authors:  Shoko Nishizawa; Mamiko Sakata-Yanagimoto; Keiichiro Hattori; Hideharu Muto; Tran Nguyen; Koji Izutsu; Kenichi Yoshida; Seishi Ogawa; Naoya Nakamura; Shigeru Chiba
Journal:  Int J Hematol       Date:  2016-12-05       Impact factor: 2.490

5.  Mutual interaction between BCL6 and microRNAs in T cell differentiation.

Authors:  Zhiyuan Wei; Weiwu Gao; Yuzhang Wu; Bing Ni; Yi Tian
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

6.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.

Authors:  Mariano G Cardenas; Wenbo Yu; Wendy Beguelin; Matthew R Teater; Huimin Geng; Rebecca L Goldstein; Erin Oswald; Katerina Hatzi; Shao-Ning Yang; Joanna Cohen; Rita Shaknovich; Kenno Vanommeslaeghe; Huimin Cheng; Dongdong Liang; Hyo Je Cho; Joshua Abbott; Wayne Tam; Wei Du; John P Leonard; Olivier Elemento; Leandro Cerchietti; Tomasz Cierpicki; Fengtian Xue; Alexander D MacKerell; Ari M Melnick
Journal:  J Clin Invest       Date:  2016-08-02       Impact factor: 14.808

7.  BCL6 is a negative prognostic factor and exhibits pro-oncogenic activity in ovarian cancer.

Authors:  Yi-Qin Wang; Mi-Die Xu; Wei-Wei Weng; Ping Wei; Yu-Si Yang; Xiang Du
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

8.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.

Authors:  Meng Li; Ying-Ling Chiang; Costas A Lyssiotis; Matthew R Teater; Jun Young Hong; Hao Shen; Ling Wang; Jing Hu; Hui Jing; Zhengming Chen; Neeraj Jain; Cihangir Duy; Sucharita J Mistry; Leandro Cerchietti; Justin R Cross; Lewis C Cantley; Michael R Green; Hening Lin; Ari M Melnick
Journal:  Cancer Cell       Date:  2019-06-10       Impact factor: 31.743

9.  Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.

Authors:  Hong Zhou; Li Yang; Qingxiu Dang; Jianfei Huang; Yuehua Cheng; Yaping Zhang; Wenyu Shi
Journal:  Cancer Biol Ther       Date:  2020-01-13       Impact factor: 4.742

Review 10.  Unmet needs in the first-line treatment of follicular lymphoma.

Authors:  C Casulo; L Nastoupil; N H Fowler; J W Friedberg; C R Flowers
Journal:  Ann Oncol       Date:  2017-09-01       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.